Want to see PAVM full AI Analyst Report?
PAVM Stock Chart & Stats
$4.74
$0.26(5.49%)
At close: 4:00 PM EDT
$4.74
$0.26(5.49%)
Day’s Range― - ―
52-Week Range$3.85 - $28.44
Previous Close$8
Volume5.54K
Average Volume (3M)377.79K
Market Cap
$41.42M
Enterprise Value$38.63
Total Cash (Recent Filing)$3.78M
Total Debt (Recent Filing)$17.07M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 17, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.36
Shares Outstanding7,995,918
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.13
Price to Sales (P/S)62.51
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.00Price Target Upside659.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$182.50K
Bulls Say, Bears Say
Bulls Say
Diversified Product PipelineProgress across four healthcare technology programs diversifies PAVmed’s development base and creates multiple paths to future commercialization, regulatory approval, partnerships or licensing rather than relying on a single device.
Lucid Commercial CoverageNew reimbursement coverage and measured EsoGuard utilization strengthen the commercial foundation for Lucid. Broader payer adoption could improve test access, support recurring volume growth and enhance the subsidiary’s strategic value.
PortIO Clinical ProgressPositive early human data reduces some clinical uncertainty and supports further regulatory engagement. A potential 510(k) route could require less time and capital than a De Novo pathway if FDA discussions confirm eligibility.
Bears Say
Severe Cash BurnCash outflows remain exceptionally large relative to the company’s revenue base, indicating substantial ongoing funding needs. This limits financial flexibility and raises the risk that future capital must be obtained before operations mature.
Minimal Revenue And LossesThe current operating model has not yet demonstrated sustainable economics: revenue is minimal, products are generating negative gross profit and development costs remain high. Durable profitability depends on successful commercialization and reimbursement expansion.
Funding And Regulatory DependenceNear-term liquidity depends partly on external reimbursement and regulatory milestones that are not guaranteed. Delays in Medicare coverage, Veris clearance or other approvals could postpone funding inflows while development and commercialization expenses continue.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $3.85 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $41.42M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Nov 17, 2026 which is in 87 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on Aug 14, 2026. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.47 by -$0.4.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.59.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 7,995,918 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.47. Following the earnings report the stock price went up 9.705%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PAVmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (659.49% Upside)
$36.00 (659.49% Upside)
Blogger Sentiment
Bearish
PAVM Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.38%
Trailing 12-Months
Company Description
PAVmed Inc
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
PAVM Company Deck
PAVM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear operational and technical progress across multiple programs (Lucid reimbursement gains, Veris commercial onboarding and device development milestones, positive first-in-human PortIO data, Octeris technical improvements) and structural financing moves. However, the company faces material near-term liquidity constraints (cash $3.8M) and depends on contingent financing events (warrants tied to a Lucid LCD and Veris FDA clearance), while R&D and operating expenses are rising and key regulatory approvals remain uncertain. Positives demonstrate momentum and multiple potential value catalysts, but funding and regulatory timing introduce significant execution risk.View all PAVM earnings summariesPAVM Stock 12 Month Forecast
Average Price Target
$36.00
▲(659.49% Upside)
Technical Analysis
InspireMD
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
QT Imaging Holdings
―
Ownership Overview
12.02% Insiders
0.27% Mutual Funds
9.94% Other Institutional Investors
76.82% Public Companies and
Individual Investors